research-focus Research Focus International Scientific Journal Research Focus 2181-3833 Ilm-fan va innovatsiyalar akademiyasi 10.66073/researchfocus.v4i11.1865 REL-A-013181 14.00.00 ВЛИЯНИЕ COVID-19 И ВАКЦИНАЦИИ ПРОТИВ SARS-COV-2 НА ЧАСТОТУ РЕАКТИВАЦИИ HERPES ZOSTER THE IMPACT OF COVID-19 AND SARS-COV-2 VACCINATION ON THE FREQUENCY OF HERPES ZOSTER REACTIVATION COVID-19 VA SARS-COV-2 GA QARSHI EMLASHNING HERPES ZOSTER REAKTIVATSIYASI CHASTOTASIGA TA‘SIRI Шохинова Анахита Шохиновна Клинический ординатор 1 курса кафедры «Дерматовенерологии и косметологии» Самаркандского государственного медицинского университета. Узбекистан, г. Самарканд, ул. Амира Темура, 18, Нарзикулов Рустам Мардонович Самаркандский государственный медицинский университет. Узбекистан, г. Самарканд, ул. Амира Темура, 18, 05 12 2025 2025 4 11 262 271 https://creativecommons.org/licenses/by/4.0 Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.

в данном исследовании проведён сравнительный клинико - иммунологический анализ частоты и течения опоясывающего герпеса у пациентов, перенёсших COVID-19 и вакцинированных против SARS-CoV-2, с целью оценки влияния этих факторов на реактивацию вируса Varicella-Zoster. Анализ проводился путём сравнения трёх групп пациентов. На основе клинических данных и лабораторных показателей определены риск реактивации, особенности течения заболевания и иммунологические изменения. Частота возникновения, тяжесть клинических проявлений и уровень специфических иммунных клеток были проанализированы с использованием статистических методов. Кроме того, выявлены ключевые факторы риска, что является важным показателем для клинического прогнозирования и профилактики.

This study presents a comparative clinical and immunological analysis of the frequency and course of herpes zoster in patients who have had COVID-19 and in those vaccinated against SARS-CoV-2, in order to assess the influence of these factors on the reactivation of the Varicella-Zoster virus. The analysis was carried out by comparing three groups of patients. On the basis of clinical data and laboratory indicators, the risk of reactivation, the features of the course of the disease and immunological changes were determined. The incidence, the severity of clinical manifestations and the level of specific immune cells were analysed using statistical methods. In addition, key risk factors were identified, which is an important indicator for clinical prognosis and prevention.

Ushbu tadqiqotda COVID-19 ni boshdan kechirgan va SARS-CoV-2 ga qarshi emlangan bemorlarda o‘rab oluvchi gerpes chastotasi va kechishining qiyosiy klinik-immunologik tahlili o‘tkazilib, bu omillarning Varicella-Zoster virusi reaktivatsiyasiga ta‘sirini baholash ko‘zda tutilgan. Tahlil bemorlarning uchta guruhini taqqoslash yo‘li bilan o‘tkazildi. Klinik ma‘lumotlar va laboratoriya ko‘rsatkichlari asosida reaktivatsiya xavfi, kasallik kechishining xususiyatlari va immunologik o‘zgarishlar aniqlandi. Kasallanish chastotasi, klinik belgilarning og‘irligi va o‘ziga xos immun hujayralar darajasi statistik usullar yordamida tahlil qilindi. Bundan tashqari, asosiy xavf omillari aniqlandi, bu esa klinik prognoz va profilaktika uchun muhim ko‘rsatkichdir.

 опоясывающий герпес вирус Varicella-Zoster COVID-19 SARS-CoV-2 вакцинация постгерпетическая невралгия клеточный иммунитет факторы риска Herpes zoster Varicella-Zoster Virus COVID-19 SARS-CoV-2 вакцинация постгерпетическая невралгия клеточный иммунитет факторы риска Herpes zoster Varicella-Zoster virusi COVID-19 SARS-CoV-2 emlash postgerpetik nevralgiya hujayrali immunitet xavf omillari Gershon A.A., Breuer J., Cohen J.I., et al. Varicella-zoster virus infection. Nat Rev Dis Primers. 2015;1:15016. Dworkin R.H., Johnson R.W., Breuer J., et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007;44(Suppl 1):S1–26. Levin M.J. Immune senescence and its role in herpes zoster. J Infect Dis. 2018;218(Suppl Gilden D., Nagel M.A., Cohrs R.J., et al. The varicella-zoster virus vasculopathies: clinical, CSF, imaging, and virologic features. Neurology. 2013;80:853–860. Thomas S.L., Hall A.J. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis. 2004;4:26–33. Chen G., Wu D., Guo W., et al. Clinical and immunologic features in severe and moderate forms of COVID-19. J Clin Invest. 2020;130(5):2620–2629. Zheng M., Gao Y., Wang G., et al. Functional exhaustion of antiviral lymphocytes in COVID- 19 patients. Cell Mol Immunol. 2020;17:533–535. Blanco-Melo D., Nilsson-Payant B.E., Liu W.-C., et al. Imbalanced host response to SARS- CoV-2 drives development of COVID-19. Cell. 2020;181:1036–1045. Saade A., Moratelli G., Azoury R., et al. Herpes zoster following COVID-19 infection: a systematic review. Dermatol Ther. 2021;34:e15036. Tammaro A., Adebanjo G.A., Parisella F.R., et al. Cutaneous manifestations in COVID-19: epidemiology and clinical features. J Eur Acad Dermatol Venereol. 2021;35:e299–e303. Maalej M., Slouma M., Ben Dhaou B., et al. Herpes zoster after SARS-CoV-2 infection: a multicenter retrospective study. Infect Dis Now. 2022;52:103–107. Elsaie M.L., Youssef E.G., Nada H.A. Herpes zoster may be a marker for underlying COVID- 19 infection. Infect Drug Resist. 2020;13:2179–2182. Wollina U., Karadağ A.S., Rowland-Payne C., et al. Herpes zoster and COVID-19: review of the literature. Dermatol Ther. 2021;34:e14982. Rodríguez-Jiménez P., Chicharro P., Cabrera L.M., et al. Varicella-zoster virus reactivation after SARS-CoV-2 infection. Int J Dermatol. 2021;60:882–884. Park A., Iwasaki A. Type I and type III interferons — induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe. 2020;27:870–878. Choudhury A., Mukherjee S. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs. J Med Virol. 2020;92:2105–2113. Furer V., Eviatar T., Zisman D., et al. Herpes zoster following BNT162b2 mRNA COVID- 19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series. Rheumatology. 2021;60(SI):SI90–SI95. Psichogiou M., Samarkos M., Mikos N., Hatzakis A. Reactivation of varicella zoster virus after vaccination against SARS-CoV-2: a systematic review. J Eur Acad Dermatol Venereol. 2022;36:1342–1354. Lee C., Cotter D., Basa J., Greenberg H.L. Varicella-zoster virus reactivation after mRNA- 1273 (Moderna) COVID-19 vaccination. Cureus. 2021;13:e14272. Chua J.V., Chen J.J. Herpes zoster reactivation after CoronaVac vaccination. J Eur Acad Dermatol Venereol. 2021;35:e620–e622. Arvin A.M. Cell-mediated immunity to varicella-zoster virus. J Infect Dis. 1992;166(Suppl Zhou R., To K.K.-W., Wong Y.-C., et al. Acute SARS-CoV-2 infection impairs dendritic cell and T cell function. Immunity. 2020;53:864–877. Netea M.G., Domínguez-Andréa J., Barreiro L.B., et al. Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020;20:375–388. Barda N., Dagan N., Ben-Shlomo Y., et al. Safety of the BNT162b2 mRNA COVID-19 vaccine in a nationwide setting. N Engl J Med. 2021;385:1078–1090. Desai H.D., Sharma K., Nayan N., et al. A systematic review on herpes zoster following COVID-19 vaccination. Int J Infect Dis. 2022;114:58–63. Debisarun P.A., Gössling K.L., Bulut O., et al. Induction of trained immunity by influenza vaccination — impact on COVID-19. Nat Microbiol. 2021;6:1098–1111.